![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Mammoth Biosciences
Main focus: Diagnostics and treatment of genetic diseases using novel Cas enzymes
Company stage: Commercial (diagnostics), pre-clinical (therapeutics)
Diseases: COVID-19 (diagnostic), otherwise undisclosed
Genome editing tool: Cas14 and CasΦ
Funding stage: Private
Location: Brisbane CA, USA
Website: https://mammoth.bio/
Partners: Vertex Pharmaceuticals, Merck, GlaxoSmithKline
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_mammothbio_f70809c695_2ff7889bc4.png)
Mammoth Biosciences is focused on discovering novel CRISPR systems for diagnostics and therapeutic applications. The company is currently developing CRISPR-Cas12, Cas13, Cas14 and CasΦ, which may provide advantages over currently used systems. The DETECTRTM platform is based on these CRISPR systems, and has so far been applied out for SARS-CoV-2 testing. Although the lead programmes remain undisclosed, the company also develops its CRISPR systems for the treatment of genetic diseases. The company is co-founded by Nobel Laureate, Jennifer Doudna.